DJIA 18,084.58 -78.41 -0.43%
NASDAQ 5,090.51 -16.08 -0.31%
S&P 500 2,115.31 -8.17 -0.38%
market minute promo


company name or ticker

Arena Pharmaceuticals: Hopes For Long-Term Value From Belviq Get A Lift From Congress

Vivus: Qsymia Sales Flatten Again - Third Place Out Of 3 Drugs Nothing To Celebrate

Novo Nordisk's Saxenda Delays Onset of Type II Diabetes - Analyst Blog

Orexigen: Contrave Sales Flattening - Europe Needed To Spur Numbers

Vivus: Qsymia Sales Win The Week, But Is It Enough?

Orexigen Therapeutics, Inc. Goes From Biotech Beauty to Dreadful Drugmaker

A double dose of bad news for the obesity drugmaker.

Orexigen Plummets After Release Of 50% Interim Results, But Is This The End?

Why Shares of Orexigen Therapeutics, Inc. Cratered Today

Orexigen Therapeutics is crashing today following more bad news for its diet pill Contrave. Here's what investors need to know right now.

Why It's Lights Out for Orexigen Therapeutics, Inc.

Orexigen Therapeutics shares tumble after the company announces the termination of a critical post-marketing approval study for Contrave.

Vivus' Stendra To Get A Re-Launch

See More Articles...